RVMD
Revolution Medicines Inc
NASDAQ · Biotechnology
$97.49
+1.34 (+1.39%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.27B | 6.60B | 6.07B |
| Net Income | 320.45M | 295.32M | 319.17M |
| EPS | — | — | — |
| Profit Margin | 4.4% | 4.5% | 5.3% |
| Rev Growth | +0.4% | +7.5% | +13.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 8.18B | 6.96B | 7.46B |
| Total Equity | 9.48B | 8.67B | 8.66B |
| D/E Ratio | 0.86 | 0.80 | 0.86 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 413.26M | 366.06M | 402.03M |
| Free Cash Flow | 328.07M | 289.36M | 393.55M |